Directorate Change

Deltex Medical Group PLC
28 July 2004






28 July 2004


            Deltex Medical Group plc ('Deltex Medical' / 'Company')


          Former Chief Executive of UK NHS joins Deltex Medical Board



Deltex Medical, the AIM listed haemodynamic monitoring company, today announces
the appointment of Professor Sir Duncan Kirkbride Nichol as a non-executive
director.



Duncan Nichol has been an influential figure in the provision of acute health
services in the UK throughout his career.  He worked for the NHS for nearly 30
years in a number of senior management roles and was Chief Executive from 1989
to 1994.  Sir Duncan, aged 63, is also currently a non-executive director of
Synergy Healthcare plc, the AIM listed provider of healthcare support services
to the NHS and, from 1994 until 2002, he was a non-executive director of BUPA,
the UK based health insurance and private hospital group.



Since 1998, Sir Duncan has been Honorary Professor in the Manchester Centre for
Healthcare Management at the University of Manchester, having previously been
its director.  He is also currently the Chairman of the Correctional Services
Accreditation Panel for Offending Behaviour Programmes and a non-executive
director of the National Offender Management Board.



Deltex Medical's Chairman, Nigel Keen, commented:



'Sir Duncan brings with him a unique perspective on the workings of the NHS and
the complex and frequently conflicting pressures facing healthcare managers and
doctors.  His expertise will enable us to further refine our innovative approach
to partnership working with the NHS as we continue to support both doctors and
managers wishing to implement haemodynamic optimisation across the UK as a
standard of care.'



Sir Duncan Nichol commented:



'I have watched Deltex Medical's progress for some time and have been impressed
with the management team's determination to create a common agenda for doctors
and managers in the delivery of better care, more cost-effectively, to patients
in the NHS and private sector.



'The Company has a simple and effective technology that provides real benefits
to patients undergoing routine moderate and major surgery and to managers who
are charged with delivering the highest possible quality of service to as many
patients as possible within tight financial controls.'



In addition to the company directorships noted above, Duncan Nichol is currently
a non-executive director of Primary Group Limited and Clinical Pathology
Limited.  In the five years prior to the date of this announcement, he was also
a non-executive director of Endospine Kinetics Limited, Dearden Management
Limited and B-Plan UK Limited.  There is no other information requiring to be
disclosed under Schedule 2, paragraph (f) of the AIM Rules.


For further information, please contact:-


Deltex Medical Group plc



Nigel Keen, Chairman

[e-mail]

01243 774 837



Andy Hill, Chief Executive

[e-mail]

01243 774 837



Ewan Phillips, Finance Director

[e-mail]

01243 774 837





Financial Dynamics

Stephanie Highett/Lucy Briggs

[e-mail]

020 7831 3113







Notes to Editors



Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.



There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQ works in a wide range of surgical procedures


  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange